The most important #indication of #liposomal #doxorubicin is the treatment of ovarian cancer, AIDS-related Kaposi’s sarcoma, multiple myeloma, and other solid tumors.
The first #FDA-approved #nanoliposomal drug is #liposomal #doxorubicin which employs 100-nm liposomes modified by #polyethylene_glycol (PEG) chains, using the PEGylation process.